Statistics for Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)
Total visits
views | |
---|---|
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance) | 218 |
Total visits per month
views | |
---|---|
June 2024 | 0 |
July 2024 | 0 |
August 2024 | 0 |
September 2024 | 0 |
October 2024 | 0 |
November 2024 | 0 |
December 2024 | 0 |
File Visits
views | |
---|---|
JCO661595.pdf | 215 |
Top country views
views | |
---|---|
United States | 177 |
Germany | 9 |
Ukraine | 6 |
Canada | 4 |
Russia | 4 |
China | 2 |
United Kingdom | 2 |
Malaysia | 1 |
Top city views
views | |
---|---|
Wilmington | 52 |
Fairfield | 31 |
Houston | 21 |
Ann Arbor | 9 |
Jacksonville | 7 |
Cambridge | 6 |
Kiez | 6 |
Kiev | 5 |
Toronto | 4 |
Lake Mary | 3 |
Saint Petersburg | 3 |
Baltimore | 2 |
Beijing | 2 |
Gunzenhausen | 2 |
San Francisco | 2 |
Costa Mesa | 1 |
Indianapolis | 1 |
Kharkov | 1 |
Liversedge | 1 |
Moscow | 1 |
New York | 1 |
Philadelphia | 1 |
Plauen | 1 |
Scottsdale | 1 |
Seremban | 1 |